Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study

ConclusionsPatients with TRD benefitted from receiving a second IND and maintenance treatment with ESK and no new safety signals were identified.

Source: CNS Drugs - August 9, 2023 Category: Neurology Source Type: research